Invest in BioNTech SE (BNTX) to keep your portfolio healthy

The price of BioNTech SE (NASDAQ: BNTX) closed at $131.96 in the last session, up 1.55% from day before closing price of $129.94. In other words, the price has increased by $+2.02 from its previous closing price. On the day, 506392 shares were traded. BNTX stock price reached its highest trading level at $132.38 during the session, while it also had its lowest trading level at $129.18.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



We take a closer look at BNTX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.45. For the most recent quarter (mrq), Quick Ratio is recorded 5.30 and its Current Ratio is at 5.40. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.

Upgrades & Downgrades

On August 17, 2022, Cowen started tracking the stock assigning a Market Perform rating and target price of $177.

Valuation Measures:

As of this moment, BioNTech’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.06, and their Forward P/E ratio for the next fiscal year is 8.97. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.63 while its Price-to-Book (P/B) ratio in mrq is 1.63.

Stock Price History:

Over the past 52 weeks, BNTX has reached a high of $188.99, while it has fallen to a 52-week low of $117.08. The 50-Day Moving Average of the stock is 139.56, while the 200-Day Moving Average is calculated to be 148.94.

Shares Statistics:

According to the various share statistics, BNTX traded on average about 703.31K shares per day over the past 3-months and 507.67k shares per day over the past 10 days. A total of 240.23M shares are outstanding, with a floating share count of 215.11M. Insiders hold about 64.01% of the company’s shares, while institutions hold 17.00% stake in the company. Shares short for BNTX as of Jan 12, 2023 were 1.57M with a Short Ratio of 1.96M, compared to 1.4M on Dec 14, 2022.

Earnings Estimates

The company has 8 analysts who recommend its stock at the moment. On average, analysts expect EPS of $8.95 for the current quarter, with a high estimate of $10.52 and a low estimate of $5.72, while EPS last year was $13.07. The consensus estimate for the next quarter is $2.97, with high estimates of $9.41 and low estimates of -$1.2.

Analysts are recommending an EPS of between $40.85 and $33.75 for the fiscal current year, implying an average EPS of $37.61. EPS for the following year is $14.89, with 14 analysts recommending between $23.27 and $3.9.

Revenue Estimates

According to 6 analysts, the current quarter’s revenue is expected to be $4.48B. It ranges from a high estimate of $5.33B to a low estimate of $3.88B. As of the current estimate, BioNTech SE’s year-ago sales were $5.64B, an estimated decrease of -20.50% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $2.78B, a decrease of -57.20% less than the figure of -$20.50% in the same quarter last year. There is a high estimate of $4.1B for the next quarter, whereas the lowest estimate is $577.77M.

A total of 15 analysts have provided revenue estimates for BNTX’s current fiscal year. The highest revenue estimate was $19.38B, while the lowest revenue estimate was $15.08B, resulting in an average revenue estimate of $17.76B. In the same quarter a year ago, actual revenue was $19.34B, down -8.10% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $8.91B in the next fiscal year. The high estimate is $14.47B and the low estimate is $4.31B. The average revenue growth estimate for next year is down -49.80% from the average revenue estimate for this year.